Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Depression

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Research Partnership

- PMLiVE

EMA backs Lundbeck’s Brintellix in depression

Drug recommended for approval to treat major depressive episodes in adults

- PMLiVE

Teva halts development of Nuvigil in bipolar disorder

Shelves plan to expand use of sleep disorder therapy

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

- PMLiVE

New vortioxetine studies reinforce efficacy in depression

Supports marketing applications from Takeda and Lundbeck

- PMLiVE

Teva suffers setback as Nuvigil fails late-stage trial

Disappointing results in treating bipolar disorder but drug development continues

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

Teva pulls generic version of antidepressant Wellbutrin XL in US

FDA says copy is not equivalent to branded drug

Lundbeck files novel antidepressant vortioxetine in EU

Could counter loss of patent for big-selling Lexapro/Cipralex

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links